Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercialising AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that the first paediatric patient has been dosed with TSHA-102 in the REVEAL Phase 1/2 paediatric trial in the United States (U.S.) evaluating the safety and preliminary efficacy of TSHA-102 in stage three female patients 5-8 years of age with Rett syndrome. The Company also announced the United Kingdom (U.K.) Medicines and Healthcare Products Regulatory Agency (MHRA) has authorized the Clinical Trial Application (CTA) for TSHA-102 in paediatric patients, enabling the expansion of the ongoing U.S. REVEAL paediatric trial into the U.K
To read the full press release click here
